Evidence-based of conjunctival COVID-19 positivity: An Italian experience: Gemelli Against COVID Group. Issue 6 (November 2021)
- Record Type:
- Journal Article
- Title:
- Evidence-based of conjunctival COVID-19 positivity: An Italian experience: Gemelli Against COVID Group. Issue 6 (November 2021)
- Main Title:
- Evidence-based of conjunctival COVID-19 positivity: An Italian experience: Gemelli Against COVID Group
- Authors:
- Savastano, Maria Cristina
Gambini, Gloria
Savastano, Alfonso
Falsini, Benedetto
De Vico, Umberto
Sanguinetti, Maurizio
Cattani, Paola
Marchetti, Simona
Larici, Anna Rita
Franceschi, Francesco
Santoliquido, Angelo
Moroni, Rossana
Cambieri, Andrea
Bellantone, Rocco
Landi, Francesco
Scambia, Giovanni
Rizzo, Stanislao - Abstract:
- Background: The possible transmission of severe acute respiratory coronavirus 2 (SARS-CoV-2) by tears and conjunctiva is still debated. Methods: Main outcome was to investigate the agreement between nasopharyngeal swab (NPs) and conjunctival swabs (Cs) in patients with SARS-CoV-2 infection. We divided patients into four groups: (1) NPs and Cs both negative (C−NF−), (2) NPs positive and Cs negative (NFs+Cs−), (3) NPs negative and Cs positive (NFs−Cs+), and (4) NPs and Cs both positive (NFs−Cs+). The secondary outcomes were to correlate Cs results with systemic clinical parameters such as: oxygen saturation (SpO2 ), dyspnea degree (DP), radiologic pulmonary impairment based on chest radiography (XR) or computed tomography (CT), blood chemistry as D-Dimer (D-Dimer), fibrinogen, ferritin, lactate dehydrogenase (LDH), and C-reactive protein (C-RP). Results: A total of 100 conjunctival swabs in 50 patients with SARS-CoV-2 have been enrolled in this interventional clinical trials. Ocular signs (conjunctivitis) were present in five patients (10%). NPs and Cs highlighted a poor level of agreement (0.025; p = 0.404). Median SpO2 levels are the highest in the NF−C− group (98%) and the lowest (90%) in the group NF+C+ ( p = 0.001). Pulmonary impairment was statistically significantly different between NFs and Cs groups ( p = 0.019). Pulmonary impairment score increased from NFs−Cs− group (3.8 ± 3.9), to NFs+Cs+ group (6.7 ± 4.1). Intensive care unit patients showed higher COVID-19 CsBackground: The possible transmission of severe acute respiratory coronavirus 2 (SARS-CoV-2) by tears and conjunctiva is still debated. Methods: Main outcome was to investigate the agreement between nasopharyngeal swab (NPs) and conjunctival swabs (Cs) in patients with SARS-CoV-2 infection. We divided patients into four groups: (1) NPs and Cs both negative (C−NF−), (2) NPs positive and Cs negative (NFs+Cs−), (3) NPs negative and Cs positive (NFs−Cs+), and (4) NPs and Cs both positive (NFs−Cs+). The secondary outcomes were to correlate Cs results with systemic clinical parameters such as: oxygen saturation (SpO2 ), dyspnea degree (DP), radiologic pulmonary impairment based on chest radiography (XR) or computed tomography (CT), blood chemistry as D-Dimer (D-Dimer), fibrinogen, ferritin, lactate dehydrogenase (LDH), and C-reactive protein (C-RP). Results: A total of 100 conjunctival swabs in 50 patients with SARS-CoV-2 have been enrolled in this interventional clinical trials. Ocular signs (conjunctivitis) were present in five patients (10%). NPs and Cs highlighted a poor level of agreement (0.025; p = 0.404). Median SpO2 levels are the highest in the NF−C− group (98%) and the lowest (90%) in the group NF+C+ ( p = 0.001). Pulmonary impairment was statistically significantly different between NFs and Cs groups ( p = 0.019). Pulmonary impairment score increased from NFs−Cs− group (3.8 ± 3.9), to NFs+Cs+ group (6.7 ± 4.1). Intensive care unit patients showed higher COVID-19 Cs positivity in conjunctiva (12.5%) against hospitalized ones (5.8%). Conclusions: In patients hospitalized for SARS-CoV-2 the virus can be detected in conjunctival swab. Intensive care unit patients may reveal a higher COVID-19 presence in the conjunctiva. The most severe pulmonary impairment can be observed in NFs and Cs positivity. Trial registration: Clinicaltrials.gov registration. Ethical committee authorization: ID number: 0013008/20 … (more)
- Is Part Of:
- European journal of ophthalmology. Volume 31:Issue 6(2021)
- Journal:
- European journal of ophthalmology
- Issue:
- Volume 31:Issue 6(2021)
- Issue Display:
- Volume 31, Issue 6 (2021)
- Year:
- 2021
- Volume:
- 31
- Issue:
- 6
- Issue Sort Value:
- 2021-0031-0006-0000
- Page Start:
- 2886
- Page End:
- 2893
- Publication Date:
- 2021-11
- Subjects:
- Conjunctival swab -- COVID-19 -- eye infection -- ophthalmologists -- precautionary measures -- personalized medicine -- SARS-CoV-2
Ophthalmology -- Periodicals
Eye -- Diseases -- Periodicals
617.7005 - Journal URLs:
- http://www.uk.sagepub.com/home.nav ↗
http://www.eur-j-ophthalmol.com/Home/Index ↗
http://journals.sagepub.com/home/ejo ↗ - DOI:
- 10.1177/1120672120976548 ↗
- Languages:
- English
- ISSNs:
- 1120-6721
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 17993.xml